Company Profile

Q Therapeutics Inc (AKA: Q Holdings Inc)
Profile last edited on: 6/17/21      CAGE: 4PTT8      UEI:

Business Identifier: Cell therapies for neurodegenerative diseases
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

615 Arapeen Drive Suite 102
Salt Lake City, UT 84108
   (801) 582-5400
Location: Single
Congr. District: 02
County: Salt Lake

Public Profile

Q Therapeutics, Inc. is organizeda rounf development of glial cell-based therapeutic products for central nervous system (CNS) disorders in which a disease or injury inhibits normal myelin growth and enzyme performance. The direct source of more than 90% of cells in the mammalian nervous system Glial cells are essential for maintaining its normal functions. Insufficient or defective myelin and/or enzyme function is responsible disorders such as multiple sclerosis, cerebral palsy, leukodystrophies, and certain lysosomal storage disorders and prevents recovery from white-matter stroke and spinal cord injury. Q Therapeutics’ technologies allow for GMP scale-up and treatment of large population disorders while holding the promise of restorative, not just preventive, therapy for these CNS conditions. Products currently under development are targeted to treat multiple sclerosis (MS), transverse myelitis, ALS (Lou Gehrig's Disease), cerebral palsy, spinal cord injury, traumatic brain injury, stroke, Parkinson's Disease and Alzheimer's Disease. In Spring 2018, the firm formed a Joint Venture with REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company,. Designated MAGiQ Therapeutics, Inc., a Japanese joint venture company. MAGiQ will develop iPSC-derived, glial-restricted progenitor cells (GRPs), in collaboration with Q Therapeutics and REPROCELL, to treat demyelinating and degenerative diseases of the C

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2010 1 NIH $118,355
Project Title: Development Of Astrocyte-Restricted Precursors For Cell Therapy And Drug Screenin
2004 1 NIH $126,563
Project Title: A novel technology for protein delivery to the CNS

Key People / Management

  Deborah A Eppstein -- President; Chief Executive Officer; Director

  Steven J Borst -- Chief Financial Officer; Vice President, Corporate Development

  James T Campanelli -- Vice President, Research & Development

  Mani Ramaswami

  Mahendra Rao -- Scientific Founder

  Robert W Sandrock -- Senior Scientist